Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From India
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Johnson & Johnson Private Limited
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Must have a confirmed diagnosis of Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)
CLL or MCL participants being newly initiated on Imbruvica treatment (ibrutinib capsule 140 mg) based on independent clinical judgment of treating physicians
You may not be if
\- Any contraindications to ibrutinib use according to the current version of the Prescribing information in India
Clareo Health | Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From India
